Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis
Background. High neutrophil to lymphocyte ratio (NLR) has shown to be a predictor of poor outcomes in various malignancies, including pancreatic cancer. Methods. We assessed 70 consecutive pts with histologically confirmed mPC who received chemotherapy with nab-paclitaxel/gemcitabine at two differen...
Saved in:
| Main Authors: | J. Ventriglia, A. Petrillo, M. Huerta Alváro, M. M. Laterza, B. Savastano, V. Gambardella, G. Tirino, L. Pompella, A. Diana, F. Iovino, T. Troiani, E. Martinelli, F. Morgillo, M. Orditura, A. Cervantes, F. Ciardiello, F. De Vita |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2018/2373868 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
by: Wenjie Liu, et al.
Published: (2025-04-01) -
Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
by: Syvart Dennen, et al.
Published: (2025-08-01) -
ABCG2 protein expression in tumors of patients with non-resectable pancreatic cancer treated with gemcitabine and nab-paclitaxel
by: Susy Shim, et al.
Published: (2025-06-01) -
Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclitaxel therapy
by: M. Sugimori, et al.
Published: (2025-09-01) -
Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer
by: Rakesh Bhatia, et al.
Published: (2025-08-01)